Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, H.[Lee, H.] | - |
dc.contributor.author | Ahn, S.[Ahn, S.] | - |
dc.contributor.author | Ann, J.[Ann, J.] | - |
dc.contributor.author | Ha, H.[Ha, H.] | - |
dc.contributor.author | Yoo, Y.D.[Yoo, Y.D.] | - |
dc.contributor.author | Kim, Y.H.[Kim, Y.H.] | - |
dc.contributor.author | Hwang, J.-Y.[Hwang, J.-Y.] | - |
dc.contributor.author | Hur, K.-H.[Hur, K.-H.] | - |
dc.contributor.author | Jang, C.-G.[Jang, C.-G.] | - |
dc.contributor.author | Pearce, L.V.[Pearce, L.V.] | - |
dc.contributor.author | Esch, T.E.[Esch, T.E.] | - |
dc.contributor.author | Lewin, N.E.[Lewin, N.E.] | - |
dc.contributor.author | Blumberg, P.M.[Blumberg, P.M.] | - |
dc.contributor.author | Lee, J.[Lee, J.] | - |
dc.date.accessioned | 2021-07-28T16:15:50Z | - |
dc.date.available | 2021-07-28T16:15:50Z | - |
dc.date.created | 2019-11-29 | - |
dc.date.issued | 2019-11-15 | - |
dc.identifier.issn | 0223-5234 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/8104 | - |
dc.description.abstract | In order to discover a novel type of analgesic, we investigated dual activity ligands with TRPV1 antagonism and mu-opioid receptor affinity with the goal of eliciting synergistic analgesia while avoiding the side effects associated with single targeting. Based on a combination approach, a series of 4-benzyl-4-(dimethylamino)piperidinyl analogues were designed, synthesized and evaluated for their receptor activities. Among them, compound 49 exhibited the most promising dual-acting activity toward TRPV1 and the mu-opioid receptor in vitro. In vivo, 49 displayed potent, dose-dependent antinociceptive activity in both the 1st and 2nd phases in the formalin assay. Consistent with its postulated mechanism, we confirmed that in vivo, as in vitro, compound 49 both antagonized TRPV1 and functioned as a mu-opioid agonist. This result indicates that dual-acting TRPV1 antagonist/mu-opioid ligands can be made and represent a new and promising class of analgesic. (C) 2019 Elsevier Masson SAS. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER | - |
dc.subject | FORMALIN TEST | - |
dc.title | Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Hwang, J.-Y.[Hwang, J.-Y.] | - |
dc.contributor.affiliatedAuthor | Hur, K.-H.[Hur, K.-H.] | - |
dc.contributor.affiliatedAuthor | Jang, C.-G.[Jang, C.-G.] | - |
dc.identifier.doi | 10.1016/j.ejmech.2019.111634 | - |
dc.identifier.scopusid | 2-s2.0-85071390137 | - |
dc.identifier.wosid | 000496896600055 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, v.182 | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | - |
dc.citation.title | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | - |
dc.citation.volume | 182 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.subject.keywordAuthor | Analgesic | - |
dc.subject.keywordAuthor | Dual-acting mechanism | - |
dc.subject.keywordAuthor | Mu-opioid receptor | - |
dc.subject.keywordAuthor | TRPV1 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.